North India Multi-Specialty Hospital Growth Equity Opportunity New

Streszczenie

Opportunity Type

Inwestycja kapitałowa

Wielkość inwestycji

Not disclosed in the supplied materials.

Kraj podatkowy

Overview

An anonymized growth-equity opportunity in a founder-led multi-specialty hospital platform expanding capacity and higher-acuity clinical services across Delhi-NCR.

No videos found.

Dokumenty

Aby pobrać dokumenty projektowe, prosimy  zapisać się Lub zalogować

Finanse

Poproś o dostęp do data room, w razie chęci zapoznania się z projektem, należy posiadać aktualny dowód środków na platformie. 

Opis

Overview

This anonymized opportunity concerns a founder-led, multi-site private hospital platform serving the Delhi-NCR region. According to owner-authorized materials dated December 2025, the platform operates multi- and super-specialty facilities and is expanding capacity across its existing network and a planned additional hospital.

Transaction structure and use of funds

The opportunity is presented as a growth equity investment. The supplied materials do not specify the current raise amount, valuation, equity stake, investor rights, governance package or definitive use-of-proceeds allocation. The business plan indicates that capital is intended to support hospital capacity expansion, advanced medical equipment, specialist recruitment, new service lines and working capital. All terms remain subject to confirmation and definitive documentation.

Investment highlights

  • Owner materials report consolidated FY25 revenue of approximately INR 2.0 billion and EBITDA of approximately INR 0.5 billion, representing an EBITDA margin of about 25%.
  • The platform had roughly 200 operating beds in FY25 and the owner plan models more than 700 operating beds after the current expansion programme.
  • Clinical focus includes internal medicine and higher-acuity specialties such as neuroscience, cardiology, gastroenterology, pulmonology, renal sciences, orthopaedics and oncology.
  • The operating model combines hospital care, referral networks, community outreach, digital patient acquisition and planned technology-enabled patient services.
  • Owner projections model consolidated revenue growth of approximately 32% CAGR from FY25 to FY30, with near-term margin compression during commissioning followed by modeled EBITDA-margin recovery. These are forecasts, not assured outcomes.

Market context

India’s Ministry of Health and Family Welfare estimates total health expenditure at INR 9.04 trillion for 2021-22, or 3.83% of GDP, with household out-of-pocket expenditure representing 39.4% of total health expenditure. The National Health Mission also maintains infrastructure and quality standards for hospital facilities. These system-level sources provide context only and do not validate the company, transaction or projections.

Execution milestones and operating model

The owner plan calls for phased commissioning of expanded capacity, greater emphasis on higher-value specialties, increased cash and insured-patient participation, specialist hiring and additional technology deployment. Timing, capex, regulatory approvals, accreditation scope and ramp-up assumptions require independent technical and commercial diligence.

Ideal investor

This opportunity may suit healthcare-focused private equity, growth equity, family offices or strategic investors able to evaluate hospital expansion, clinical governance, regulatory compliance, doctor recruitment, payor mix, working-capital intensity and multi-year execution risk in India. It is not suitable for investors requiring liquid securities or independently audited forward projections at the initial screening stage.

Material risks and dependencies

  • The current raise amount, valuation, dilution, governance rights and exit framework are not specified.
  • Historical and projected operating data are owner-provided and require financial, tax and commercial diligence.
  • Construction, commissioning, capex overrun and occupancy-ramp risks.
  • Recruitment and retention of specialist doctors, nurses and clinical staff.
  • Licensing, accreditation, clinical-quality, patient-safety and regulatory risks.
  • Geographic concentration in Delhi-NCR and exposure to local competition.
  • Payor-mix, government-reimbursement, insurer-collection and receivables risks.
  • Execution risk associated with new specialties, oncology infrastructure and digital initiatives.

Public sources

Market context: Ministry of Health and Family Welfare, National Health Accounts Estimates for India 2021-22; National Health Mission, Indian Public Health Standards.

Przegląd rynku

No market overview found.

Competition Analysis

No competitor analysis found.

Finanse

Tylko inwestorzy mogą przeglądać dane finansowe.

Major Benefits in this Opportunity

  • Owner-reported FY25 revenue of approximately INR 2.0 billion and EBITDA margin of about 25%.
  • Phased expansion from roughly 200 operating beds to more than 700 in the owner business plan.
  • Exposure to higher-acuity specialties and a multi-channel patient-acquisition model.
  • Owner-modeled revenue growth of approximately 32% CAGR through FY30, subject to execution and forecast risk.

Who is it Ideal for?

Healthcare-focused private equity, growth equity, family offices or strategic investors able to underwrite hospital expansion, clinical governance, regulatory compliance, working-capital intensity and multi-year execution risk in India.

Zarządzanie i zespół

No management team information provided.

Potencjalne zachęty do inwestowania w

Zachęty inwestycyjne w

Możesz zostać zakwalifikowany do...

No investment incentives found.

Możesz sprawdzić dostępne opcje finansowania za pośrednictwem naszej platformy internetowej, połączonej z ponad 4500 lokalnymi bankami i pożyczkodawcami na całym świecie.

No bank options found.

Our network of Advisors will help you in gaining the benefits from Tax incentives.

No tax incentives found.

Other Options and Incentives.

Ryzyko związane z tą szansą

Są to ryzyka, które zdaniem naszych ekspertów należy wziąć pod uwagę przed dokonaniem inwestycji w tym przypadku...

  • Transaction size, valuation, dilution, governance rights and exit framework are unspecified.
  • Owner-provided historical and projected data require independent verification.
  • Construction, commissioning, capex-overrun and occupancy-ramp risk.
  • Clinical staffing, licensing, accreditation, quality and patient-safety risk.
  • Delhi-NCR concentration and competitive-market risk.
  • Payor-mix, reimbursement, receivables and working-capital risk.
  • Execution risk in new specialties, oncology infrastructure and digital initiatives.
Nowe aktualizacje dotyczące tej możliwości

W tej sekcji znajdziesz najnowsze zmiany i aktualizacje dotyczące tej możliwości inwestycyjnej. 

Support at Najafi capital

Jesteśmy tutaj, aby pomóc

Porozmawiaj ze swoim dedykowanym doradcą na temat swojej prośby.

Dodatkowe koszty transakcyjne w

Each Transaction has some additional hidden costs, that the investors should know. At Najafi Capital we tried to Unveil them as much as possible. The non percentage values in the report are in USD.

No additional costs found.

Przedstawione koszty wskazują typowe scenariusze, ale rzeczywiste wydatki mogą się różnić w zależności od kilku czynników, w tym pilności transakcji, narodowości zaangażowanych stron i innych szczególnych okoliczności. Powyższa lista nie obejmuje wszystkich potencjalnych wydatków.

Zweryfikowane usługi, których możesz potrzebować

We focus on working with Local professional agencies to decrease the cost of your operations. You can work with Big 4, or experience the same quality with lower fees.

No service providers found.

Zapytanie o więcej informacji

Questions that you should know...

No FAQs available for this opportunity.

Znajdź możliwości w różnych branżach:

  • All
  • Diversified Real Estate Activities
  • Energy Sector
  • Oil and Gas Drilling
  • Oil and Gas Equipment and Services
  • Pharmaceuticals
  • Pharmaceuticals Industry
  • Real Estate Sector
  • energy Group
  • pharmaceuticals, biotechnology and life sciences Group

Zastrzeżenia Autor: najafi.capital

This content has been prepared by or on behalf of an associate of Najafi Capital (“Najafi”) and is provided solely for informational purposes. Nothing contained herein constitutes, or should be construed as, an offer to sell or a solicitation of an offer to buy any security, nor a recommendation to subscribe for, acquire, or dispose of any investment or investment strategy.

Information presented on this page is based on materials and data provided by the project owner or issuer of the relevant investment opportunity and is used by Najafi as part of its project screening and high-level due diligence process. While Najafi believes such information to have been obtained from sources deemed reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or reliability of such information. Najafi expressly disclaims any responsibility or liability for the accuracy, legality, or completeness of information provided by the project owner or for any subsequent updates or statements made by such parties.

Najafi does not provide investment, legal, tax, or accounting advice and does not act in a fiduciary capacity. Prospective investors are solely responsible for conducting their own independent due diligence and for verifying all information relevant to any investment decision.

Investing in private market opportunities involves substantial risk, including the potential loss of all invested capital, illiquidity, and the absence of any guarantee of returns or distributions. Prospective investors should carefully evaluate these risks and consult with their own independent financial, legal, tax, and accounting advisors to determine whether any investment is suitable in light of their individual circumstances. (Last Update: January 2026)

pl_PLPolish
Investment Finder Wizard

Kreator wyszukiwania inwestycji

Obsługiwane przez Google GemniAI, kontrolowane przez ekspertów

Jaki jest Twój główny cel Inwestycyjny?

Wielkość inwestycji

W jakiej branży?

Które kraje preferujesz?

Możesz określić region lub opisać go terminami takimi jak „kraje germańskie”, „kraje o łagodnej pogodzie”...

Twój dostosowany plan inwestycyjny jest już w drodze!

Wkrótce nasz zespół przeanalizuje Twoje cele i preferencje inwestycyjne, aby zapewnić Ci kompleksowy raport przedstawiający idealne jurysdykcje, strategie inwestycyjne i potencjalne możliwości dostosowane do wybranych branż. Bądź na bieżąco, aby uzyskać wnikliwe wskazówki dostosowane do Twoich konkretnych potrzeb.